company background image
AGY

Allergy Therapeutics AIM:AGY Stock Report

Last Price

UK£0.19

Market Cap

UK£124.0m

7D

1.3%

1Y

-33.6%

Updated

15 Aug, 2022

Data

Company Financials +
AGY fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

AGY Stock Overview

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments.

Allergy Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Allergy Therapeutics
Historical stock prices
Current Share PriceUK£0.19
52 Week HighUK£0.41
52 Week LowUK£0.16
Beta1.44
1 Month Change10.00%
3 Month Change-12.50%
1 Year Change-33.62%
3 Year Change63.83%
5 Year Change-33.04%
Change since IPO-74.16%

Recent News & Updates

Shareholder Returns

AGYGB PharmaceuticalsGB Market
7D1.3%-2.6%0.03%
1Y-33.6%5.7%-8.3%

Return vs Industry: AGY underperformed the UK Pharmaceuticals industry which returned 5.2% over the past year.

Return vs Market: AGY underperformed the UK Market which returned -9% over the past year.

Price Volatility

Is AGY's price volatile compared to industry and market?
AGY volatility
AGY Average Weekly Movement3.7%
Pharmaceuticals Industry Average Movement6.4%
Market Average Movement5.4%
10% most volatile stocks in GB Market10.8%
10% least volatile stocks in GB Market2.7%

Stable Share Price: AGY is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: AGY's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004600Manuel Llobethttps://www.allergytherapeutics.com

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut.

Allergy Therapeutics plc Fundamentals Summary

How do Allergy Therapeutics's earnings and revenue compare to its market cap?
AGY fundamental statistics
Market CapUK£123.97m
Earnings (TTM)-UK£5.38m
Revenue (TTM)UK£79.00m

1.6x

P/S Ratio

-23.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AGY income statement (TTM)
RevenueUK£79.00m
Cost of RevenueUK£23.10m
Gross ProfitUK£55.89m
Other ExpensesUK£61.27m
Earnings-UK£5.38m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0083
Gross Margin70.75%
Net Profit Margin-6.81%
Debt/Equity Ratio5.2%

How did AGY perform over the long term?

See historical performance and comparison